The role of imatinib plasma level testing in gastrointestinal stromal tumor
- 280 Downloads
The management of patients with gastrointestinal stromal tumor (GIST) has markedly advanced over the past 10 years. Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and PDGFRA which is found in the majority of patients with GIST. Although some patients may experience prolonged disease control while on imatinib, most patients will develop imatinib resistance within 2–3 years on therapy. A recent retrospective analysis demonstrated a relationship between imatinib plasma levels and progression-free survival in patients with advanced GIST. Plasma imatinib levels in this study were unrelated to the daily administered dose of imatinib. A prospective trial is underway in order to evaluate whether modification of imatinib dose to achieve a target imatinib plasma level will impact patient outcome when compared to standard imatinib dosing in GIST (http://www.clinicaltrials.gov, NCT01031628). This review will explore the current available data on the relationship between imatinib plasma levels, response to treatment, and other prognositic factors as well as discuss the implications of this data for possible future therapeutic approaches.
KeywordsGIST Imatinib Blood levels Prognostic factors Therapy Dosing
Logistical support during submission of this article was provided by Springer Healthcare LLC. This support was funded by Novartis.
Conflict of interest
Dr. Suzanne George: Novartis and Pfizer Advisory Boards; Dr. Jonathan C. Trent: I have clinical trial support, honoraria from Novartis Pharmaceuticals. I have laboratory support from Merck Pharmaceuticals.
- 2.Blanke C, Demetri G, Von Mehren M et al (2008) Long-term results from a randomized phase ii trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JCO 25:620–625Google Scholar
- 13.Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) EORTC soft tissue and bone sarcoma group; The Italian sarcoma group; Australasian gastrointestinal trials group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093–1103CrossRefPubMedGoogle Scholar
- 15.Heinrich M, Owzar K, Corless C et al (2008) Correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: calgb 150105 study by cancer and leukemia group B and Southwest oncology group. JCO 26:5360–5367CrossRefGoogle Scholar
- 29.Gardner ER, Burger H, van Schiek RH et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharm Ther 80(20):192–201Google Scholar
- 32.Van Glabbeke M, Verweij J, Casali PG et al (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European organisation for research and treatment of cancer-Italian sarcoma group-Australasian gastrointestinal trials group study. J Clin Oncol 23(24):5795–5804CrossRefPubMedGoogle Scholar